From an economic perspective, first-line prostate-specific antigen (PSA) testing is favored over biparametric magnetic resonance imaging (bpMRI) for prostate cancer screening, mainly due to ...
Risankizumab is an effective treatment option for patients with psoriatic arthritis (PsA), according to a recent meta-analysis. Risankizumab showed superior efficacy across multiple outcomes compared ...
CHICAGO—PSA levels at the time of initial screening among men aged 44-50 years can accurately predict the risk that a man will die from prostate cancer (PCa) or develop metastatic PCa up to 30 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results